Comparison of the effectiveness and safety of cranberry with tamsulosin and placebo in improving symptoms associated with ureteral stents.

Comparative study of the effectiveness and safety of cranberry with tamsulosin and placebo in improving stent-related symptoms in patients undergoing Double-J ureteral stent placement: a three-group randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090427001853N20

Enrollment

Registered

2025-05-13

Start date

2025-05-15

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Urinary tract symptoms due to double-J stent insertion. Condition 2: Urinary tract symptoms due to double-J stent insertion. Condition 3: Urinary tract symptoms due to double-J stent insertion. Condition 4: Urinary tract symptoms due to double-J stent insertion. Condition 5: Urinary tract symptoms due to double-J stent insertion. Pain associated with micturition Dysuria Painful micturition, unspecified Hematuria Other symptoms and signs involving the genitourinary system

Interventions

Intervention 1: Intervention group 1: daily receiving one 500 mg cranberry capsule of Dayan Pharmed Behin Tolid company, from the first day after stent placement until the stent removal. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age over 18 years Candidate for Double-J Ureteral Stent Placement

Exclusion criteria

Exclusion criteria: Insertion of bilateral stents Concurrent urinary tract infection Pregnancy Neurogenic bladder Overactive bladder syndrome History of or current treatment for urinary incontinence Lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) Chronic pelvic pain syndrome Use of anticholinergic, alpha-blockers, and analgesics drugs Major complications after urethroscopy surgery (such as perforation, .....)

Design outcomes

Primary

Measure	Time frame
Dysuria. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Hematuria. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Frequency. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Nocturia. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Pain. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Sexual dysfunction. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).	—

Measure

Time frame

Dysuria. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Hematuria. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Frequency. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Nocturia. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Pain. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).;Sexual dysfunction. Timepoint: 3 and 7 days after the start of the intervention and after the end of the intervention. Method of measurement: Ureteral Stent Symptom Questionnaire (USSQ).

—

Secondary

Measure	Time frame
Drug side effects. Timepoint: From the start of the intervention to the end of the intervention. Method of measurement: Patient report in person or by phone.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariman Asheghpour

Rasht University of Medical Sciences

farimanasheghpour1371@gmail.com+98 13 3352 5259

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026